What is HC Wainwright’s Estimate for CMPX Q1 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Compass Therapeutics in a research report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.11) EPS.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01.

A number of other brokerages also recently weighed in on CMPX. Wall Street Zen raised Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 16th. Craig Hallum initiated coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They set a “buy” rating and a $15.00 price objective for the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $9.00 target price on shares of Compass Therapeutics in a research report on Thursday. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a report on Tuesday, January 6th. Finally, Citigroup initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Compass Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $13.00.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $5.53 on Friday. The firm has a market cap of $983.57 million, a PE ratio of -12.29 and a beta of 1.48. The firm’s 50 day moving average price is $5.89 and its 200 day moving average price is $4.78. Compass Therapeutics has a twelve month low of $1.33 and a twelve month high of $6.88.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CMPX. Caitong International Asset Management Co. Ltd acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $132,000. Seven Fleet Capital Management LP acquired a new position in Compass Therapeutics in the 4th quarter worth $3,054,000. Invesco Ltd. raised its position in Compass Therapeutics by 5.3% in the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after buying an additional 3,245 shares during the last quarter. XTX Topco Ltd lifted its position in Compass Therapeutics by 582.2% during the 4th quarter. XTX Topco Ltd now owns 115,634 shares of the company’s stock worth $621,000 after buying an additional 98,684 shares in the last quarter. Finally, Ikarian Capital LLC acquired a new position in shares of Compass Therapeutics during the 4th quarter worth about $4,296,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.